SEC Form 4 · accession 0001209191-15-024793
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J Swanson
Officer — Senior Vice President, Researc
Period of report
Mar 6, 2015
Accepted (ET)
Mar 10, 2015 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.59 | Mar 6, 2015 | A | 350,000 | A | — | Mar 5, 2025 | Common Stock | 350,000 | 350,000 | D |
Explanation of responses
- F1The option vests in one annual installment of 87,500 shares on March 6, 2016 and in equal monthly installments for the three years thereafter.